ATE384126T1 - Interferon induzierende genetisch veränderte attenuierte viren - Google Patents

Interferon induzierende genetisch veränderte attenuierte viren

Info

Publication number
ATE384126T1
ATE384126T1 AT99927440T AT99927440T ATE384126T1 AT E384126 T1 ATE384126 T1 AT E384126T1 AT 99927440 T AT99927440 T AT 99927440T AT 99927440 T AT99927440 T AT 99927440T AT E384126 T1 ATE384126 T1 AT E384126T1
Authority
AT
Austria
Prior art keywords
interferon
genetically modified
recombinant dna
viral
dna techniques
Prior art date
Application number
AT99927440T
Other languages
English (en)
Inventor
Andrej Y Egorov
Thomas Muster
Adolfo Garcia-Sastre
Peter Palese
Sabine Brandt
Original Assignee
Sinai School Medicine
Egorov Andrej Y Dr
Thomas Muster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine, Egorov Andrej Y Dr, Thomas Muster filed Critical Sinai School Medicine
Application granted granted Critical
Publication of ATE384126T1 publication Critical patent/ATE384126T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99927440T 1998-06-12 1999-06-11 Interferon induzierende genetisch veränderte attenuierte viren ATE384126T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8910398P 1998-06-12 1998-06-12

Publications (1)

Publication Number Publication Date
ATE384126T1 true ATE384126T1 (de) 2008-02-15

Family

ID=22215706

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99927440T ATE384126T1 (de) 1998-06-12 1999-06-11 Interferon induzierende genetisch veränderte attenuierte viren

Country Status (12)

Country Link
US (2) US6468544B1 (de)
EP (1) EP1098961B1 (de)
JP (1) JP4441595B2 (de)
AT (1) ATE384126T1 (de)
AU (1) AU748416B2 (de)
CA (1) CA2334857C (de)
DE (1) DE69937999T2 (de)
DK (1) DK1098961T3 (de)
ES (1) ES2301241T3 (de)
PT (1) PT1098961E (de)
WO (1) WO1999064571A1 (de)
ZA (1) ZA200007403B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468544B1 (en) * 1998-06-12 2002-10-22 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
PT1085904E (pt) * 1998-06-12 2013-03-05 Sinai School Medicine Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
WO2001064860A2 (en) * 2000-03-02 2001-09-07 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US7247619B2 (en) * 2000-05-19 2007-07-24 Univ Leland Stanford Junior Viral vectors useful in induction of humoral or cellular immunity
US20040198146A1 (en) * 2002-12-05 2004-10-07 Murray Robert H. Safe toy balloon closure and sealing device and assemblies using same
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
ES2319424T3 (es) 2003-03-27 2009-05-07 Ottawa Health Research Institute Virus mutantes de la estomatitis vesivular y sus usos.
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CN102727880A (zh) 2004-06-01 2012-10-17 西奈山医学院 遗传工程猪流感病毒及其应用
EP1855713B1 (de) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Gentechnisch hergestellter pferde-influenza-virus und seine verwendungen
AT502275B8 (de) * 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
EP2064229B1 (de) 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Onkolytisches rhabdovirus
EP1911836A1 (de) 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Mediumzusatz für die Virusproduktion
TW200909581A (en) * 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
EP2045323A1 (de) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linearische Expressionskonstrukte zur Herstellung von Partikeln des Influenzavirus
EP2048237A1 (de) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replikationsdefizienter Influenza-Virus zur Expression heterologer Sequenzen
EP2072058A1 (de) 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modifiziertes Influenzavirus
US8883479B2 (en) 2008-11-25 2014-11-11 Baxter Healthcare Sa Method for production of pH stable enveloped viruses
EP2233568A1 (de) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Neues Verfahren zur Herstellung eines RNA Virus
CN107365751B (zh) 2008-12-16 2021-07-09 纳米医疗公司 流感疫苗的生产
EP2233152A1 (de) 2009-03-24 2010-09-29 Avir Green Hills Biotechnology Research Development Trade Ag Schnell wachsender reassortanter Influenza-A-Virus
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
WO2011009864A1 (en) 2009-07-22 2011-01-27 Avir Green Hills Biotechnology Research Development Trade Ag Novel influenza virus
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
JP2013500712A (ja) 2009-07-31 2013-01-10 ノバルティス アーゲー 逆遺伝学系
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US20130183740A1 (en) 2010-06-02 2013-07-18 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
EP2820126B1 (de) 2012-03-02 2017-05-17 Seqirus UK Limited Reassortment von influenzaviren
KR20150110494A (ko) 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스
EP2934581B1 (de) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenzavirus-impfstoffe und verwendungen davon
BR112015021880A2 (pt) 2013-03-13 2017-09-26 Novartis Ag rearranjo de vírus influenza b
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
US10029005B2 (en) 2015-02-26 2018-07-24 Boehringer Ingelheim Vetmedica Gmbh Bivalent swine influenza virus vaccine
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
CN108603188A (zh) * 2015-11-24 2018-09-28 联邦科学技术研究组织 在细胞培养物中产生病毒
EP3471767A4 (de) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenzavirus-hämagglutinin-proteine und verwendungen davon
EP3559216A1 (de) 2016-12-22 2019-10-30 Blue Sky Vaccines GmbH Verfahren zur reinigung eines virus
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN111527202B (zh) 2017-11-08 2024-03-29 蓝天免疫疗法有限责任公司 So3色谱在病毒纯化方法中的应用
EP3810634A4 (de) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaik-influenzavirus-hämagglutinin-polypeptide und deren verwendungen
CN113853215B (zh) 2019-01-24 2025-07-18 蓝天免疫疗法有限责任公司 高生长流感病毒
CN115896035B (zh) * 2022-12-22 2024-04-16 苏州沃美生物有限公司 一种应用于病毒扩增的Vero细胞株、其构建方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5939831A (ja) 1982-08-27 1984-03-05 Biseibutsu Kagaku Kenkyusho:Kk 豚用インフルエンザウイルス不活化ワクチン
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
DE570357T1 (de) 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
EP0932684A2 (de) 1996-09-27 1999-08-04 American Cyanamid Company Mutationen in der genomischen 3'promoterregion und im polymerasegen, die für die attenuierung von viren der ordnung mononegavirales verantwortlich sind
KR100702523B1 (ko) 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법
JP4434478B2 (ja) 1997-07-11 2010-03-17 イエール ユニバーシティー リエンジニアリングされた外被を有するラブドウイルス
CA2302867A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
US6468544B1 (en) * 1998-06-12 2002-10-22 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses

Also Published As

Publication number Publication date
AU4434199A (en) 1999-12-30
CA2334857A1 (en) 1999-12-16
DE69937999D1 (de) 2008-03-06
US6866853B2 (en) 2005-03-15
JP4441595B2 (ja) 2010-03-31
DE69937999T2 (de) 2009-01-29
US20030157131A1 (en) 2003-08-21
CA2334857C (en) 2012-03-20
EP1098961A1 (de) 2001-05-16
ZA200007403B (en) 2001-09-03
AU748416B2 (en) 2002-06-06
US6468544B1 (en) 2002-10-22
JP2002517230A (ja) 2002-06-18
EP1098961A4 (de) 2001-09-12
DK1098961T3 (da) 2008-05-26
ES2301241T3 (es) 2008-06-16
PT1098961E (pt) 2008-04-23
WO1999064571A1 (en) 1999-12-16
EP1098961B1 (de) 2008-01-16

Similar Documents

Publication Publication Date Title
ATE384126T1 (de) Interferon induzierende genetisch veränderte attenuierte viren
Yuan et al. Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system
Gissi et al. The complete mitochondrial DNA sequence of the rabbit, Oryctolagus cuniculus
DE60334310D1 (de) Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
DK0702085T3 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
JP2009540801A5 (de)
JP2019536462A5 (de)
DE60143564D1 (de) Veränderte rekombinasen zur modifizierung des genoms
WO2003092594A3 (en) Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
ATE142700T1 (de) Genetische manipulationen mit von rna-viren abgeleiteten sequenzen enthaltendem rekombinantem dna
EP0910406A4 (de) Rekombinante kaninchen-herpesviren
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
ATE399210T1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
MXPA05005202A (es) Vacuna.
JP2004501646A5 (de)
WO2023155901A1 (en) Mutant cytidine deaminases with improved editing precision
YU80500A (sh) Vakcina izazvana sojem virusa hepatitisa b i njeno dobijanje
TR200101445T2 (tr) Kararlı, zayıflatılmış kuduz virüsü mutantları ve bu mutantların canlı aşıları
WO1999057284A3 (en) Attenuated influenza viruses
TR200201081A2 (tr) Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları
ATE232238T1 (de) Synthetische promotoren von herpes simplex virus

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1098961

Country of ref document: EP

EEFA Change of the company name